Skip to main content

Table 5 Literature reviews of metformin and breast cancer

From: Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes

Study Year Study population of breast cancer Number (met/non-met/non-DM) DFS CSS OS Follow up (months or years) HR (met versus non-met)1; 95 % CI Special subgroup Duration of metformin treatment Tumor characteristics
He et al. [15] 2012 Stage II, HER2+ only 88/66/1829 N Y Y 47.6 OS (HR 0.52; 0.28 to 0.97)   NA Done
CSS (HR 0.47; 0.24 to 0.90)
Bayraktar et al. [17] 2012 Triple-negative only 63/67/1318 Y Y Y 62 OS (HR 1.22; 0.66 to 2.28)   NA Done
RFS (HR 1.37; 0.78 to 2.40)
DMFS (HR 1.63; 0.87 to 3.06)
Peeters et al. [12] 2013 All 508/550/NA N Y Y   OS (HR 0.74; 0.58 to 0.96) Increased risk in the first 12 months after discontinuation Done NA
CSS (HR 0.88; 0.59 to 1.29)
Lega et al. [14] 2013 All 1094/1267/NA N Y Y 4.5 (years) OS (HR 0.97; 0.92 to 1.02)   Done NA
CSS (HR 0.91; 0.81 to 1.03)
Hou et al. [18] 2013 All 419/594/4612 N N Y 68 OS2 (HR 0.762; 0.6 to 0.986)   NA Done
OS3 (HR 1.708; 1.461 to 1.997)
Xiao et al. [19] 2014 Luminal 275/405/5105 N Y Y 70 OS (HR 3.579; 1.506 to 8.506) luminal A   NA Done
OS (HR 3.232;1.839 to 5.678) luminal B (high Ki67)
OS (HR 2.034;1.019 to 4.059) Luminal B (HER2+)
Kim et al. (present study)   All 202/184/6581 Y Y Y 100 OS (HR 1.87;1.25 to 2.81) 1.Hormone receptor+/HER2 + NA Done
CSS (HR1.85;1.17 to 2.92) 2.Chemotherapy and endocrine therapy
DFS (HR 1.59, 1.06 to 2.39)
  1. 1Hazard ratio (HR) for metformin (met) versus non-metformin (non-met) (reference): He et al., Peeters et al., Lega et al. HR for non-metformin versus metformin (reference): Bayraktar et al. Xiao et al., Present study
  2. 2Metformin versus non diabetes mellitus (DM) (reference) 3Non-metformin versus non diabetes mellitus (reference). OS, overall survival; CSS, cancer-specific survival; DMFS, distant metastasis-free survival; RFS, relapse-free survival; DFS, disease-free survival; HER2, human epidermal growth factor receptor-2
  3. NA, Not applicable